An Early-Onset Advanced Rectal Cancer Patient With Increased KRAS Gene Copy Number Showed A Primary Resistance to Cetuximab in Combination With Chemotherapy: A Case Report
Mutations in KRAS (codon 12/13), NRAS, BRAFV600E, and amplification of ERBB2 and MET account for 70–80% of anti-epidermal growth factor receptor (EGFR) monoclonal antibody primary resistance. However, the list of anti-EGFR monoclonal antibody primary resistance biomarkers is still incomplete. Herein...
Guardado en:
Autores principales: | Tian Fang, Tingting Liang, Yizhuo Wang, Haitao Wu, Shuhan Liu, Linying Xie, Zhihao Zhang, Jiaying Liang, Cheng Yao, Yehui Tan, Chang Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/641d4f9bb7764406b13f2d1505420918 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Interleukin‐33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer
por: Xujun Zhang, et al.
Publicado: (2021) -
Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
por: Elli Narvi, et al.
Publicado: (2018) -
Low-Coverage Whole Genome Sequencing Using Laser Capture Microscopy with Combined Digital Droplet PCR: An Effective Tool to Study Copy Number and Kras Mutations in Early Lung Adenocarcinoma Development
por: Elizabeth A. Mickler, et al.
Publicado: (2021) -
KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection
por: Olga I. Brovkina, et al.
Publicado: (2021) -
Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
por: Li B, et al.
Publicado: (2018)